BRAF and cholangiocarcinoma: A total of 21% of patients were identified as having actionable alterations in BRAF, ERBB2, FGFR2, and IDH1. Additionally, ctDNA mutations compared to tissue mutations had a concordance of 74% in all patients and 92% in the intrahepatic CCA cohort [20].